Fenwick-Led Stoke Therapeutics Prices Upsized $142M IPO
Venture-backed Stoke Therapeutics Inc., a biotechnology firm developing therapies for genetic diseases, went public Wednesday after raising $142 million in an upsized initial public offering, steered by Fenwick & West LLP...To view the full article, register now.
Already a subscriber? Click here to view full article